Regulatory T cells (Tregs) are essential for resolving inflammation and maintaining immune homeostasis. How Tregs are locally regulated in inflamed niches is poorly understood, although their expression of CD4 helper T (Th) cell lineage-defining transcription factors (i.e. Gata3, Rorγt, and Tbet) tailors their regulatory function towards a specific type of [READ MORE]
Viral modulation of type II interferon increases T cell adhesion and virus spread Herpes and poxviruses express viroceptors, viral proteins that bind cytokines and modulate their activity. Until now, all known viroceptors that bind interferon (IFN) have been discovered exclusively in poxviruses and inhibit IFN activity through blocking the cytokine-receptor [READ MORE]
On June 18, ICIS hosted the first-ever IL-9-focused symposium at the Federation of Clinical Immunology Societies (FOCIS) annual meeting. Devotees of all things IL-9 gathered in San Francisco to hear about “IL-9: from birth to breath.” The symposium was organized by IL-9 guru Mark Kaplan and newcomer (and Signals+ Co-Editor [READ MORE]
Christopher Hunter is recognized for contributions to T cell immunology with the 2024 Matis Family Institute for Immunology Investigator Award. The award was presented at the Institute’s Year in Review Symposium on June 6th. [READ MORE]
On May 2, 2023, NIAMS Scientific Director of Intramural Research, Dr. John O’Shea, was elected to the U.S. National Academy of Sciences at the conclusion of the Academy’s 160th annual meeting. This designation – considered one of the highest honors that a scientist can achieve – recognizes distinguished and continuing achievements in original research. [READ MORE]
Christopher Garcia is the 2024 Passano Award winner in recognition for his research into the way molecules bind to one another and its implications for safer and more effective treatments. [READ MORE]
ICIS Member and 2019 Milstein Award Winner, Professor Akiko Iwasaki, renowned immunologist, has been named to both the TIME100 and TIME100 Health, two of Time Magazine’s lists of the most influential people of 2024. The honor recognizes her pioneering research into post-acute infection syndromes like LongCOVID. [READ MORE]
Dr. Georg Schett, a world renown rheumatologist at the University Hospital Erlangen in Germany who chaired Cytokines 20219 in Vienna, has been named to Time Magazine’s 100 Most Influential People in Health for 2024 for his work using CAR T therapy to treat Autoimmune Diseases. Dr. Schett saw the potential of new immune-based therapy CAR T which dramatically improved outcomes for patients with certain blood cancers that involve B cells, like leukemia and lymphoma, as a promising treatment for autoimmune diseases like lupus, in which immune B cells attack the body’s own cells. He performed the first CAR T treatments on five patients with the disease in 2022. Eight months after receiving the therapy, all five were in remission and no longer needed powerful immunosuppressive drugs to control their disease. Last year, Schett published a second groundbreaking study showing that another small group of patients receiving the therapy were still in remission more than two years later without immunosuppressive drugs. [READ MORE]
AAI 2024 Distinguished Lecturer Christopher A. Hunter: From parasites to mRNA vaccines: cytokine networks that dictate T cell tempo IL27 centric, great data with classic immunology experiments leading to promising new therapies.
Dr. Brian Kim on the left, and Dr. David Artis on the right at their visit in February to Allen Institute in Seattle, WA. Photo from Dr Kim’s Twitter/X account.
Some dermatological disorders such as atopic dermatitis, alopecia areater, and vitiligo have few treatments available due to the lack of effective medications currently on the market. However, this might change soon with the formation of a new biotech entity called Alys Pharmaceuticals, Inc. that launched on 12th of February. It started with a substantial 100-million-dollar investment from Medicxi, the European healthcare investment fund, with the goal of transforming the treatment paradigm for several dermatology indications of significant prevalence and major unmet need. Alys, based in Boston and Geneva, is the combination of the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics, and has a world class leadership team that brings together experts across dermatology and advanced scientific fields. [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
